5:23 PM
 | 
May 02, 2013
 |  BC Extra  |  Company News

G-BA issues three benefit assessments

Germany's Federal Joint Committee (G-BA) issued final assessments for three drugs on Thursday. G-BA said Xalkori crizotinib from Pfizer Inc. (NYSE:PFE) has "significant" additional benefit over docetaxel or pemetrexed-containing chemotherapy in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase ( ALK)-positive -- Xalkori's approved indication. In a February preliminary assessment, the Institute for Quality and Efficiency in Healthcare (IQWiG) said the drug had "no additional benefit" over comparators in the...

Read the full 386 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >